Host-virus interaction: a new role for microRNAs by Scaria, Vinod et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Retrovirology
Open Access Review
Host-virus interaction: a new role for microRNAs
Vinod Scaria, Manoj Hariharan, Souvik Maiti, Beena Pillai and 
Samir K Brahmachari*
Address: GN Ramachandran Knowledge Center for Genome Informatics, Institute of Genomics and Integrative Biology, CSIR, Mall Road, Delhi 
110 007, India
Email: Vinod Scaria - vinods@igib.res.in; Manoj Hariharan - manoj@igib.res.in; Souvik Maiti - souvik@igib.res.in; 
Beena Pillai - beenapillai@igib.res.in; Samir K Brahmachari* - skb@igib.res.in
* Corresponding author    
Abstract
MicroRNAs (miRNAs) are a new class of 18–23 nucleotide long non-coding RNAs that play critical
roles in a wide spectrum of biological processes. Recent reports also throw light into the role of
microRNAs as critical effectors in the intricate host-pathogen interaction networks. Evidence
suggests that both virus and hosts encode microRNAs. The exclusive dependence of viruses on the
host cellular machinery for their propagation and survival also make them highly susceptible to the
vagaries of the cellular environment like small RNA mediated interference. It also gives the virus an
opportunity to fight and/or modulate the host to suite its needs. Thus the range of interactions
possible through miRNA-mRNA cross-talk at the host-pathogen interface is large. These
interactions can be further fine-tuned in the host by changes in gene expression, mutations and
polymorphisms. In the pathogen, the high rate of mutations adds to the complexity of the
interaction network. Though evidence regarding microRNA mediated cross-talk in viral infections
is just emerging, it offers an immense opportunity not only to understand the intricacies of host-
pathogen interactions, and possible explanations to viral tropism, latency and oncogenesis, but also
to develop novel biomarkers and therapeutics.
Background
MicroRNAs (miRNAs) are small RNA molecules which
have recently gained widespread attention as critical regu-
lators in complex gene regulatory networks in eukaryotes.
These small RNA, processed from non-coding regions of
the genome into 18–23 nucleotide long single stranded
RNA, have been shown to regulate translation of messen-
ger RNA (mRNA) by binding to it and effecting target
cleavage or translational block depending on the extent of
sequence complementarity with the target [1]. Generally,
in mammalian systems, microRNAs bind to targets with
incomplete complementarity, in association with a host
of cellular proteins – what is commonly termed as the
RNA Induced Silencing Complex (RISC).
MicroRNA mediated regulation has been lately shown to
encompass a wide spectrum of host biological processes
ranging from growth and development to oncogenesis [2-
5]. Recent genome-wide computational screens for micro-
RNA targets in humans predict that 10% [6] to 30% [7] of
all genes are regulated by microRNAs. The regulatory net-
work of miRNA-mRNA interaction is rendered even more
complex because of multiplicity and cooperativity of
microRNA targeting.
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MicroRNAs have recently been implicated in the intricate
cross-talk between the host and the pathogen [8] in viral
infections and is thought to play a major role in viral
pathogenesis. Though studies into the entire spectrum of
host-pathogen interactions at the microRNA level are still
in its infancy, there has been a recent spurt in reports
exploring the possibility in a number of major pathogenic
viruses of humans.
MicroRNAs were initially discovered in 1993, in a genetic
screen for mutants that disrupt the timing of post-embry-
onic development in the nematode Caenorhabditis elegans
[9], and were thought to be an oddity in gene regulation,
of nematodes till 2000. About 7 years later, when let7 was
discovered [10], and was found to be highly conserved in
eukaryotes, it led to a surge in discovery of new microR-
NAs in a number of organisms including humans.
Biogenesis and mechanism of action of 
microRNAs
MicroRNA gene location
MicroRNAs have been classically thought to be tran-
scribed from intergenic regions, but recent large-scale
genome-wide cloning experiments [11] have shown that
microRNAs can be derived from introns as well. Intergenic
microRNAs are sometimes found to occur as clusters
which would be transcribed as polycistronic transcripts
and are shown to share similar expression profiles [12]. A
significant proportion of microRNAs are encoded within
the introns of protein-coding genes, presumably
expressed in sync with them. A few microRNAs have been
mapped to the exons of protein-coding genes. One exam-
ple is hsa-mir-20a which is annotated by miRBase to arise
from the exon 2 as well as introns 5 and 8 of alternative
transcripts of C13orf25. The significance of these microR-
NAs and their roles in alternatively spliced transcripts are
yet to be addressed.
Maturation
MicroRNAs are transcribed by RNA Polymerase II as pri-
mary microRNAs (pri-miRNAs) which range from hun-
dreds to thousands of nucleotides in length and resemble
protein-coding transcripts in that they are poly-ade-
nylated and capped [1]. These pri-miRNAs are then proc-
essed by nuclear localized enzymes Drosha or Pasha
(DGCR8 in humans) to produce thermodynamically sta-
ble hairpin structures known as pre-microRNAs (pre-miR-
NAs), of ~70 bases. These pre-microRNAs are then
exported to the cytoplasm by Exportin-5 and are then fur-
ther processed by the RNAase III enzyme Dicer, to form
duplexes of 18–23 bases. This duplex is unwound by a yet
to be discovered helicase. In steps shared with the siRNA
(small interfering RNA) pathway the strand with lower
stability in the 5' end (guide strand) is preferentially
selected [13] from the double stranded molecule (which
composes of miRNA and its complementary strand
miRNA*) to be associated with the RNA Induced Silenc-
ing Complex (RISC).
Mechanisms of action
The mechanism of action of microRNAs is considered to
be by two modes – translational repression and target deg-
radation. The former is common in mammalian systems
while the latter is found predominantly in plants. The
basic difference in the two mechanisms is thought to be
primarily governed by the levels of complementarity
between microRNAs and their target transcripts. Perfect or
near perfect complementarity as is common in plant
microRNAs and in a small class of eukaryotic microRNAs
causes target cleavage and degradation [14], analogous to
the action of siRNAs which have perfect complementarity
to the target regions. Evidence suggests that microRNA
bound transcripts are sequestrated into P bodies [15,16]
where they are maintained in a silenced state either by
associating with proteins that prevent translation or pos-
sibly by removal of the cap structure [16].
In fact, one microRNA can have binding sites in multiple
targets (in humans, this comes to hundreds) and one tar-
get can be repressed by multiple microRNAs (multiplicity
and co-operativity) [6]. Moreover, the target repression is
likely to be dosage dependent, adding to the complexity
of the network of genetic regulation. Recent evidence also
suggests an overdose of artificial short hairpin RNAs (shR-
NAs) can saturate the RNA interference machinery [17].
This would have far reaching implications on determining
dosage of artificial microRNAs for therapeutics as well as
for experimental research. The biogenesis and action is
summarized in Figure 1.
Non-classical mechanisms of action
Recent evidence suggests that microRNAs can also regu-
late protein expression through non-classical ways.
Genome-wide expression analysis of microRNA targets
have shown to decrease the transcript levels [18]. But
whether this is a direct or indirect effect is yet to be
explored. A couple of recent reports also suggest that
microRNAs can modulate de-adenylation of transcripts
[19,20]. MicroRNAs are classically thought to be negative
regulators, but with exceptions as in the case of a reported
human microRNA which can cause abundance of Hepati-
tis RNA [21] (vide infra). A recent report by Bhattacharyya
et al suggests that microRNA mediated mechanism of
post-transcriptional repression of gene expression is
indeed reversible [22], suggesting that the proteins associ-
ated with microRNA-mRNA complex modulate the
expression of the transcript in a switch-like mechanism,
responding to particular stimuli. This mechanism, if
proved to be a generalized phenomenon, would have
large implications in the regulation of gene expression inRetrovirology 2006, 3:68 http://www.retrovirology.com/content/3/1/68
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relation to particular stimuli. In summary microRNAs can
act as a trans-acting element for reversible and dynamic
regulation of spatial and temporal protein expression.
Computational tools for discovery of microRNA 
and their targets
Computational predictions have been the mainstay for
discovery of microRNAs and their targets. The algorithms
for microRNA prediction range from custom-made pro-
grams to search for hairpin loops and energetic stability to
advanced algorithms employing machine learning
approaches [23-25]. Even though the algorithms for
microRNA prediction have improved over time, accurate
de novo prediction of microRNA still remains a challeng-
ing task. This is especially important in the case of viruses
as viral microRNAs do not share close homology even in
the same class. We hope the prediction algorithms will
improve with a better understanding of the sequence and
structural components of precursor hairpins involved in
microRNA biogenesis [26]. We have recently developed a
de novo method (unpublished results) for microRNA pre-
diction in viruses based on Support Vector Machines,
rationalizing that virus encoded microRNA precursor
hairpins would share the sequence and structure features
with that of host as they share the same microRNA
processing machinery. The algorithms for microRNA tar-
get prediction also have been significantly improved from
first-generation algorithms which rely on sequence com-
plementarity rules, thermodynamic stability and conser-
vation [6,27,28] by incorporation of features like target
RNA structure [29].
MicroRNAs as an antiviral defense mechanism
Viruses are obligate intracellular parasites and use the cel-
lular machinery for their survival and replication. The suc-
cess of the virus essentially depends on its ability to
Schematic overview of biogenesis and action of microRNAs in eukaryotic cells Figure 1
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effectively and efficiently use the host machinery to prop-
agate itself. This dependence on the host also makes it sus-
ceptible to the host gene-regulatory mechanisms. Though
the gene regulatory mechanisms involving both host and
viral proteins have been extensively studied, data on small
RNA mediated gene regulation in viral infections is just
emerging. Interestingly, it seems that the cellular microR-
NAs, in addition to their normal regulatory roles in cellu-
lar gene expression also double up as fortuitous agents
that target foreign nucleic acids, as in the case of viruses.
The inventory of microRNAs encoded differs between cell
types, and thus may contribute to the tissue tropism of
viruses. Some of these are elaborated in the subsequent
sections.
Primate Foamy Virus
Lecellier et al [30], for the first time demonstrated that a
mammalian microRNA, mir-32 restricts the accumulation
of the retrovirus primate foamy virus type 1 (PFV-1) in
human cells. PFV is a retro-transcribing virus similar to the
Human Immunodeficiency Virus (HIV), but codes for two
additional proteins, Tas and Bet. Insights into the possible
role of microRNAs came from the observation that cell
lines which express a protein, which interferes with the
RNA mediated silencing machinery, showed higher accu-
mulation of PFV-1. Disruption of the target site in a
mutant of PFV allowed it to accumulate much faster than
the wild type, in infected cells. The group also demon-
strated that Tas could act as a non-specific suppressor of
RNA interference and could demonstrate that mir-32
related translational block was indeed higher in Tas(-)
cells where Tas was not expressed. This report not only
throws light into the role of microRNAs in antiviral
defense, but also into how viruses have evolved to offset
the effects of RNA interference by encoding suppressors of
interference.
Human Immunodeficiency Virus
We have earlier shown [31], using robust computational
tools, that involve consensus prediction approaches that
five human encoded microRNAs can potentially target the
entire repertoire of accessory genes in HIV, including nef.
The targets were found to be highly conserved in all of the
viral clade sequences with the exception of clade O. The
fact that defective nef is well known to be associated with
a long term non-progressor state led us to speculate that
the levels of the cellular microRNAs would be a decisive
factor in determining the progression of the disease. The
targets have been experimentally validated (unpublished
results) by cloning the target site in the 3'UTR of Green
Fluorescent Protein (GFP) reporter gene. Analysis of pre-
viously reported microarray data [32] of these microRNAs
in T Cells, demonstrated that the microRNA levels are
indeed variable among individuals. Although it is
believed that HIV encodes for suppressors of RNAi [33]
(vide infra), recent microarray data on microRNA gene
expression levels in HIV infected human cells [34] show
that above five human encoded microRNAs are down reg-
ulated.
Influenza virus
Through computational methods incorporating both con-
sensus prediction and target accessibility, we have found
that human encoded microRNAs could target critical
genes involved in the pathogenesis and tropism of Influ-
enza virus A/H5N1 (unpublished results). Two human
encoded microRNAs mir-507 and mir-136 had potential
binding sites in Polymerase B2 (PB2) and Hemagglutinin
(HA) genes respectively. The target regions in the respec-
tive genes were not only found to be conserved across dif-
ferent viral strains, but were also found to fall in highly
accessible regions of the predicted target RNA structure.
Moreover, analysis of previously reported [35] microarray
data on microRNA gene expression in different tissues has
shown that mir-136 is expressed in lung.
Both the genes PB2 and HA are known to be critical for the
pathogenicity of the virus. While HA is the surface glyco-
protein involved in direct binding of the virus to the cell
surface, HA in the H5N1 subtype carries a polybasic site,
cleavage at which, by cellular proteases is an essential step
in establishing infection. PB2 is one of the three compo-
nents of the Ribonucleoprotein which is responsible for
RNA replication and transcription. Recent evidence, from
recombinant viruses generated by combinations of
murine and avian viruses identified PB2 as one of the two
genes associated with virulence. The polymerase activity
was directly correlated with the high virulence of the
murine strain in their cognate host [36]. Another interest-
ing feature is that these microRNAs were found to be
absent in the chicken genome, although a large number of
human microRNAs (160 of 336 human microRNAs) have
homologs in the chicken genome implicating them in the
difference in infectivity and lethality of the virus in
chicken and human.
Mammalian microRNAs as positive regulators
Hepatitis C virus
Jopling et al [21] reported an interesting case wherein the
tissue specificity of microRNA expression was exploited by
a virus to establish tissue selectivity. A liver specific micro-
RNA mir-122 was shown to cause accumulation of viral
RNA by binding to the 5' non-coding region of the viral
genome. The authors have also verified the findings by
mutational analysis as well as sequestration of the micro-
RNA. It is possible that this novel mechanism of microR-
NAs targeting the 5'UTR of the transcript may be mediated
through a translation controlling switch at the 5'end of
the transcript through changes in RNA secondary struc-
ture. This, by and large, remains the only report of aRetrovirology 2006, 3:68 http://www.retrovirology.com/content/3/1/68
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microRNA targeting the 5'UTR in a mammalian system
and causing RNA accumulation.
Viral suppressors of RNAi mediated gene 
silencing
Interestingly viruses have also evolved to evade RNAi by a
variety of strategies. The suppressors of antiviral RNAi is
better understood in plant viruses. To counteract the small
RNA mediated interference, viruses express suppressors
that interfere with microRNA as well as siRNA pathways
[37]. The virus encoded antiviral RNAi suppressors
include small RNAs to proteins, and are thought to effect
through various mechanisms like sequestration and/or
inhibition of siRNA formation [38-40]. The entire spec-
trum of suppressors of RNAi encoded by animal viruses is
yet to be unraveled.
Virus encoded microRNAs
The interest in discovering novel microRNA candidates
using both computational tools and experimental valida-
tion of the predicted candidates have shown that viruses
also encode microRNAs (see Table 1). Most of these pre-
dictions have been successfully validated using experi-
mental approaches. The current understanding of virus
encoded microRNAs is limited mainly to the Herpes virus
family, which is a unique class of viruses whose members
are implicated in a number of major pathogenic states in
humans ranging from mild infections to oncogenesis.
Other viruses with miRNA mediated regulation include
major pathogens like HIV and Simian Virus 40 (SV40)
[41]. SV40 encoded microRNAs which are generated dur-
ing the late phase in life cycle could target the early tran-
scripts including those coding for viral T antigens and
mediate evasion of the virus infected cells from cytotoxic
T cells.
Interestingly the viral microRNAs, unlike their vertebrate
counterparts do not share a high level of homology, even
within members of the same family or with that of the
host. This has been attributed to the higher rate of muta-
tions and the faster evolution in viruses as compared to
eukaryotes. Though this would mean an evolutionary
advantage to rapidly adapt to the host and environmental
conditions, it offers a challenge to computational biolo-
gists as most of the algorithms for microRNA prediction
relies heavily on conservation and would prove inade-
quate in case of viruses. This would be just the tip of the
iceberg as de novo prediction of microRNA candidates is
still an unmet challenge for computational biologists.
With the advent of high throughput validation methods
like microarrays being employed, and with better and effi-
cient computational algorithms for prediction of microR-
NAs, the count is all set to rise. Similarly there is a severe
gap in the understanding the targets of these microRNAs
and necessitates the use of better technology clubbed with
efficient computational algorithms.
Regulation of cellular processes by virus encoded 
microRNA
Bennasser et al [33] reported a computational screen for
HIV-1 encoded microRNAs and further went about pre-
dicting their cellular targets and found five pre-miRNA
candidates which has potential to encode 10 microRNAs
and through them regulate ~1000 host transcripts. In a
similar computational screen for targets to potential HIV
encoded microRNA, Couturier et al [47] showed that the
HIV pro-viral genome had multiple matches of comple-
mentarity in important cellular proteins/cytokines well
known to play crucial roles in HIV pathogenesis like
CD28, CD40L, IL-2, IL-3, TNF-β, IL-12 and CD4. The cur-
rent understanding is that multiple gapped stretches of
complementarity can result in translational repression,
along with the discovery that the HIV-1 pro-viral genome
has such levels of complementarity especially with human
protein coding genes, points to the possibility that HIV
transcripts may encode for microRNAs, or small regula-
tory RNAs. This along with the evidence that a large
number of these cellular genes including CD28 are well
documented to be down regulated in HIV pathogenesis,
points to the possible cross-talk between the virus and
host at the microRNA level.
Of late, Cui et al discovered novel virus encoded microR-
NAs from HSV genome [44]. Subsequently Gupta et al,
discovered that Herpes simplex-1 (HSV-1) latency associ-
ated transcript (LAT) encodes for a microRNA which tar-
Table 1: List of virus-encoded microRNAs
Source Virus Virus Type Number of microRNAs References
Epstein Barr virus Herpesvirus 32 [42]
Kaposi sarcoma-associated herpesvirus Herpesvirus 17 [43]
Mouse gammaherpesvirus Herpesvirus 10 [42]
Human cytomegalovirus Herpesvirus 14 [42]
Herpes Simplex-1 Herpesvirus 1 [44]
Rhesus lymphocryptovirus Herpesvirus 22 [45]
Simian virus 40 Papovavirus 2 [41]
Human Immunodeficiency Virus Retrovirus 1 [46]Retrovirology 2006, 3:68 http://www.retrovirology.com/content/3/1/68
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get critical genes of the apoptosis pathway [48] including
those involved in the TGF-β signaling pathway, including
TGF-β1 and SMAD3, thereby protecting the cells from
apoptosis. This is perhaps the first experimental evidence
of a virus encoded microRNA targeting cellular transcripts.
Such a mechanism could operate in other related herpes
viruses like Epstein-Barr virus, which not only causes
latent infection, but also associated with a wide spectrum
of neoplasms in humans including Burkitts lymphoma
and nasopharyngeal carcinoma. It is all the more proba-
ble that oncogenic herpes viruses like EBV and KSHV
encoded microRNAs can target critical genes involved in
oncogenesis. This is especially so in the case of EBV
encoded microRNAs as they have been shown to be differ-
entially expressed in different phases of the viral life [45].
Our analysis of cellular targets of 32 EBV encoded micro-
RNAs using robust computational approaches using con-
sensus of microRNA target prediction software revealed
that the target genes are involved in apoptosis and tumor
suppressor pathways, suggesting that EBV encoded micro-
RNAs play crucial roles in oncogenic transformation
induced by the virus (unpublished results). The discovery
of virus encoded microRNAs playing crucial roles in
pathogenesis of diseases caused by viruses not only
throws light on a new level of host-pathogen interactions,
but also would help in designing novel preventive and
therapeutic strategies.
Viral gene regulation by virus-encoded microRNAs
Omoto et al, using a combinatorial approach incorporat-
ing both computational prediction and experimental val-
idation demonstrated the possibility that a virus-encoded
microRNA could auto-regulate itself. A nef derived micro-
RNA could down regulate nef expression in vitro suggest-
ing that it could be a mechanism of maintaining low
viremia in Long term non-progressor (LTNP) states [46].
This finding was later expanded by the same group with
an additional discovery that nef derived microRNA also
suppress transcription [49] by reducing HIV-1 promoter
activity through the negative responsive element in the 5'-
LTR, thus contributing to an additional layer of auto reg-
ulation.
In yet another instance, a virus encoded microRNA, is
effectively used by the virus to tune down a set of genes
and thereby evade cytotoxic T cell response [41]. Simian
Virus 40 (SV40) was shown to produce a microRNA which
was primarily expressed in the late stages of infection.
Curiously, the expression of the viral microRNAs did not
have any untoward effect on the viral replication. Further
analysis revealed that the microRNAs had near perfect
complementary matches in the early expressed genes of
the virus which would target them for interference medi-
ated degradation. The genes include the T antigen which
is a determinant for invasion of T cells, thus providing an
advantage in camouflaging the virus infected cells from
the cellular immune system.
MicroRNAs as biomarkers and therapeutics
Recently microRNA expression profiles have been ana-
lyzed for viral infections like HIV [34]. MicroRNA expres-
sion has been shown to be specific to various stages of
infection in Herpesviruses [45] and have been proposed
to be associated with latency in HIV infection [31,50],
promising an early biomarker for cancers caused by onco-
genic viruses. MicroRNA profiles have also been explored
in a number of patho-physiological conditions [51].
Recent reports suggest that microRNA profiles can be used
not only to classify different classes of cancers [52-54], but
could also be used as biomarkers for diagnosis and prog-
nosis of disease states [54].
MicroRNAs and anti-microRNA oligonucleotides (AMOs)
have been proposed as novel therapeutics [55,56]. Recent
advances in nucleotide chemistry like Locked Nucleic
Acids (LNA) [57], and other backbone modifications have
made it possible to design small RNA oligonucleotides
which are highly stable in biological systems circumvent-
ing one major hurdle in using microRNAs as future thera-
peutics. Oligonucleotide modifications have already
made their way to the microRNA experimental biologists
workbench [58]. The success of siRNA based strategies in
targeting specific genes could be extended to microRNAs
also. This would include delivery strategies [34]. This
would be even more important as siRNA based therapeu-
tics for viral pathogens in different stages of clinical trials
and are showing promising results.
Artificial microRNAs (amiRNAs) and microRNA 
engineering
MicroRNAs are promising candidates for developing
novel bio-therapeutics against viruses, as it requires only
partial complementarity unlike siRNAs and thus can
tackle the high rate of mutations in viruses better than siR-
NAs. Initial experiments creating microRNAs based on
siRNA design rules have shown promising results [59].
Our group has recently developed an algorithm for design
of highly specific microRNAs on against sequences to be
targeted (unpublished results). This would allow design
of microRNAs against highly conserved sequences in viral
genome. Artificial microRNAs also offer the advantage
that they can be optimized to create less off-target events
in the host thus substantially reducing untoward side
effects. MicroRNAs or microRNA target sequences could
also be engineered into transforming viruses and could
enable tissue specific and environment sensitive expres-
sion of genes.Retrovirology 2006, 3:68 http://www.retrovirology.com/content/3/1/68
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Integrative approach to modeling microRNA 
mediated host-virus interaction
With evidence demonstrating that both host encoded and
virus encoded microRNAs interact with host and virus
transcripts respectively, in addition to their roles in regu-
lating their own transcripts warrants a comprehensive
analysis of host and virus microRNAs and their targets to
elucidate a holistic picture of microRNA mediated host-
virus interaction model (Figure 2). The challenge would
be to integrate bioinformatics with gene expression and
proteomics data. This would not only enable them to
design novel diagnostic and therapeutic strategies to com-
bat deadly viruses, but also empower researchers to under-
stand basic biological processes involved in latency and
oncogenic transformation mediated by viruses.
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